Edward F. Webb

2.1k citations

36 papers · 1.7k indexed · h-index 20

Molecular Biology top 10%
Physiology top 5%
Immunology top 10%
Organic Chemistry top 10%
Oncology top 10%

Co-authors: Don E. Griswold John C. Lee Jerry L. Adams Douglas W.P. Hay David C. Underwood Ruth R. Osborn Steven Bochnowicz David J. Rieman
Topics: Receptor Mechanisms and Signaling (8 papers)Neuropeptides and Animal Physiology (8 papers)Asthma and respiratory diseases (8 papers)
Cited by: Immunology and Allergy Immunology Physiology
Journals: Journal of Medicinal Chemistry Journal of Pharmacology and Experimental Therapeutics Journal of Investigative Dermatology
Partner nations: United States United Kingdom Canada

In The Last Decade

Edward F. Webb

36 papers receiving 1.7k citations

Peers

Countries citing papers authored by Edward F. Webb

Since Specialization

Citations

This map shows the geographic impact of Edward F. Webb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward F. Webb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward F. Webb more than expected).

Fields of papers citing papers by Edward F. Webb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward F. Webb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward F. Webb. The network helps show where Edward F. Webb may publish in the future.

Co-authorship network of co-authors of Edward F. Webb

This figure shows the co-authorship network connecting the top 25 collaborators of Edward F. Webb. A scholar is included among the top collaborators of Edward F. Webb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward F. Webb. Edward F. Webb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacological Characterization of GSK573719 (Umeclidinium): A Novel, Long-Acting, Inhaled Antagonist of the Muscarinic Cholinergic Receptors for Treatment of Pulmonary Diseases 2013 ·Journal of Pharmacology and Experimental Therapeutics ·M Salmon,Mark A. Luttmann,James J. Foley,Peter T. Buckley,Dulcie B. Schmidt,Miriam Burman,Edward F. Webb,(unknown),Charles J. Kotzer,Victoria J. Barrett,Robert J. Slack,Henry M. Sarau,Michael R. Palovich,Dramane I. Lainé,Douglas W.P. Hay,William L. Rumsey	64
2	Tyrosine urea muscarinic acetylcholine receptor antagonists: Achiral quaternary ammonium groups 2012 ·Bioorganic & Medicinal Chemistry Letters ·Qi Jin,(unknown),(unknown),Jian Jin,Yonghui Wang,Katherine L. Widdowson,Michael R. Palovich,James J. Foley,Dulcie B. Schmidt,Peter T. Buckley,Edward F. Webb,M Salmon,Kristen E. Belmonte,Henry M. Sarau,Jakob Busch‐Petersen	3
3	Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD 2009 ·Bioorganic & Medicinal Chemistry Letters ·Zehong Wan,Dramane I. Lainé,Hongxing Yan,(unknown),Katherine L. Widdowson,Peter T. Buckley,Miriam Burman,James J. Foley,Henry M. Sarau,Dulcie B. Schmidt,Edward F. Webb,Kristen E. Belmonte,Michael R. Palovich	2
4	Design, Synthesis, and Structure−Activity Relationship of Tropane Muscarinic Acetylcholine Receptor Antagonists 2009 ·Journal of Medicinal Chemistry ·Dramane I. Lainé,Zehong Wan,Hongxing Yan,(unknown),Haibo Xie,Wei Fu,Jakob Busch‐Petersen,(unknown),(unknown),Katherine L. Widdowson,Frank E. Blaney,James J. Foley,(unknown),Edward F. Webb,Mark A. Luttmann,Miriam Burman,Henry M. Sarau,M Salmon,Michael R. Palovich,Kristen E. Belmonte	9
5	Discovery of novel 8-azoniabicyclo[3.2.1]octane carbamates as muscarinic acetylcholine receptor antagonists 2007 ·Bioorganic & Medicinal Chemistry Letters ·Dramane I. Lainé,Haibo Xie,(unknown),James J. Foley,Peter T. Buckley,Edward F. Webb,Katherine L. Widdowson,Michael R. Palovich,Kristen E. Belmonte	7
6	Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity 2001 ·Bioorganic & Medicinal Chemistry Letters ·Jerry L. Adams,Jeffrey C. Boehm,Timothy F. Gallagher,Shouki Kassis,Edward F. Webb,Ralph Hall,Margaret E. Sorenson,Ravi S. Garigipati,Don E. Griswold,John C. Lee	89
7	Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis 2000 ·Arthritis & Rheumatism ·Alison M. Badger,Don E. Griswold,Rasesh Kapadia,Simon Blake,Barbara A. Swift,(unknown),George B. Stroup,Edward F. Webb,David J. Rieman,Maxine Gowen,Jeffrey C. Boehm,Jerry L. Adams,John C. Lee	186
8	SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistence 2000 ·Journal of Pharmacology and Experimental Therapeutics ·David C. Underwood,Ruth R. Osborn,Charles J. Kotzer,Jerry L. Adams,John C. Lee,Edward F. Webb,Donald C. Carpenter,Steven Bochnowicz,Heath C. Thomas,Douglas W.P. Hay,Don E. Griswold	216
9	In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4receptor antagonist with anti-inflammatory activity 1999 ·Prostaglandins Leukotrienes and Essential Fatty Acids ·Henry M. Sarau,James J. Foley,Dulcie B. Schmidt,Lenox D. Martin,Edward F. Webb,Maritsa N. Tzimas,John Breton,Marie Chabot‐Fletcher,David C. Underwood,Douglas W.P. Hay,William D. Kingsbury,Pamela A. Chambers,Israil Pendrak,Dalia R. Jakas,Ganesh M. Sathe,(unknown),R. A. DAINES,(unknown)	6
10	Pyrimidinylimidazole inhibitors of CSBP/P38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes 1998 ·Bioorganic & Medicinal Chemistry Letters ·Jerry L. Adams,Jeffrey C. Boehm,Shouki Kassis,Peter D. Gorycki,Edward F. Webb,Ralph Hall,Margaret E. Sorenson,John C. Lee,Andrew D. Ayrton,Don E. Griswold,Timothy F. Gallagher	88
11	Intralesional Cytokines in Chronic Oxazolone-Induced Contact Sensitivity Suggest Roles for Tumor Necrosis Factor α and Interleukin-4 1998 ·Journal of Investigative Dermatology ·Edward F. Webb,Maritsa N. Tzimas,Don E. Griswold,S J Newsholme	61
12	Antiinflammatory activity of topical auranofin in arachidonic acid‐ and phorbol ester‐induced inflammation in mice 1995 ·Drug Development Research ·Don E. Griswold,Marie Chabot‐Fletcher,Edward F. Webb,Lenox D. Martin,Leonard M. Hillegass	1
13	Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses 1994 ·International Journal of Immunopharmacology ·Manjula Reddy,Edward F. Webb,David R. Cassatt,(unknown),(unknown),Don E. Griswold,Alemseged Truneh	22
14	Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response 1993 ·Inflammation ·Don E. Griswold,Edward F. Webb,John Breton,John R. White,Paul Marshall,Theodore J. Torphy	72
15	Beneficial effects of SK&K 105685 in rat adjuvant arthritis: Prophylactic and therapeutic effects on disease parameter progression 1993 ·International Journal of Immunopharmacology ·A M Badger,Barbara A. Swift,Edward F. Webb,Robert Clark,Peter J. Bugelski,Don E. Griswold	5
16	Pharmacology of the pyrroloimidazole, SK&F 105809—II 1991 ·Biochemical Pharmacology ·(unknown),Paul Marshall,(unknown),Edward F. Webb,Leonard M. Hillegass,(unknown),John F. Newton,Nabil Hanna	28
17	Analgetic Activity of SK&F 105809, a Dual Inhibitor of Arachidonic Acid Metabolism 1991 ·Birkhäuser Basel eBooks ·D.E. Griswold,Paul Marshall,Lenox D. Martin,Edward F. Webb,(unknown)	14
18	Inhibition of inflammatory cell infiltration by bicyclic imidazoles, SK&F 86002 and SK&F 104493 1989 ·Inflammation ·Don E. Griswold,Sylvia Hoffstein,Paul Marshall,Edward F. Webb,Leonard M. Hillegass,Paul E. Bender,Nabil Hanna	16
19	SK&F 86002: A structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid 1987 ·Biochemical Pharmacology ·Don E. Griswold,Paul Marshall,Edward F. Webb,(unknown),John F. Newton,Michael J. DiMartino,Henry M. Sarau,John G. Gleason,George Poste,Nabil Hanna	68
20	Inhibition of carrageenan-induced inflammation by urethan anesthesia in adrenalectomized and shamoperated rats 1982 ·Journal of Pharmacological Methods ·Don E. Griswold,Sarah Alessi,Edward F. Webb,D. T. Walz	16

About Edward F. Webb

Edward F. Webb is a scholar working on Pharmacology, Biochemistry and Cellular and Molecular Neuroscience, having authored 36 papers that have together received 1.7k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (8 papers), Neuropeptides and Animal Physiology (8 papers) and Asthma and respiratory diseases (8 papers). The work is most often cited by research in Immunology and Allergy (113 citations), Immunology (341 citations) and Physiology (402 citations). Edward F. Webb has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Don E. Griswold, John C. Lee, Jerry L. Adams, Douglas W.P. Hay, David C. Underwood, Ruth R. Osborn, Steven Bochnowicz, David J. Rieman, Jeffrey C. Boehm and Paul Marshall. Their work appears in journals such as Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and Journal of Investigative Dermatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact